Materials and Methods
Materials hTERT-BJ cells were a gift from Dr. Robert A. Weinberg (Whitehead Institute for Biomedical Research). Mouse anti-human antibodies J143 (4th International Workshop on Leukocytes), SAM-1 (5th International Workshop on Leukocytes), #481709 (R&D Systems), LM142 (EMD Millipore) and TS2/4 1 were from the indicated sources. FITC-conjugated goat anti-mouse IgG was purchased from Sigma. α 5 specific blocking antibody mAb16 was purified from hybridoma provided to us by Dr. Kenneth M. Yamada. α 4 specific antibody Natalizumab was from commercial source.
Negative stain electron microscopy (EM) EM specimen preparation, data collection and processing were as described 2 .
Isothermal titration calorimetry (ITC) ITC was performed in buffer containing 20 mM Tris (pH 7.4), 150 mM NaCl, 1 mM CaCl 2 and 1 mM MgCl 2 at 25°C with 20 injections (2 µL each) on MicroCal iTC200. Data were fit to the one-site binding model 3 in OriginPro 7.
Protein and carbohydrate composition Unclasped α 5 β 1 ectodomain with shaved (30 µg), high-mannose (60 µg), and complex (30 µg) N-glycans were separately loaded on an Agilent liquid chromatography system equipped with a TSKgel BioAssist G4SWXL analytical size exclusion column (Tosoh Bioscience), a DAWN HELEOS II multi-angle light scattering detector, an Optilab T-rEX refractive index detector and a variable wavelength UV detector (Wyatt Technology Corporation). Data were processed in ASTRA 6 using the protein conjugate model (d /d = 0.185 and 0.145 for protein and carbohydrate components, respectively) 4 .
Staining integrin subunits on cell surface Surface expression of integrin α 3 -, α 5 -, α 8 -and α V -subunits on K562, HEK293 and hTERT-BJ cells was quantified by immuno-staining. β 1 integrins with the latter three α-subunits bind ligands containing the Arg-Gly-Asp (RGD) motif 5 . Cells (10 6 /mL in PBS supplemented with 50 mg/mL BSA and 1 mg/mL Na 3 N) were incubated on ice with 50 µg/mL human IgG for 20 min to block Fc-receptors, then incubated with 2.5 µg/mL primary antibodies J143 (anti-α 3 ), SAM-1 (anti-α 5 ), #481709 (anti-α 8 ), LM142 (anti-α V ) or TS2/4 (anti-α L ) for 30 min, followed by 3 washes. Cells were then incubated with 2 µg/mL FITC-conjugated goat anti-mouse IgG for 30 min, followed by 3 washes, and subjected to flow cytometry (BD FACSCanto II). Staining lymphocyte integrin subunit α L was a negative control.
Quantitative comparison of α 5 -, α 4 -and β 1 subunit expression levels on K562 and Jurkat cells was the same as described about except that cells were only incubated with 3.75 µg/mL Alexa647-conjugated primary antibodies before subject to washing and flow cytometry.
Supplementary Text
EC 50 or affinity of Fabs for α 5 β 1 and Eqs. S1-S11 For soluble α 5 β 1 ectodomain or headpiece proteins, 20 nM α 5 β 1 (or 100 nM α 5 β 1 with closure-stabilizing Fabs) were equilibrated with 0-10,000 nM of Fabs for 2 hr. The mixture was then incubated with 5 nM FITC-cRGD for 2 hr, and FP was measured. Fab-binding was reported by changes in FP. For intact α 5 β 1 , K562 cells (2×10 6 cells/mL) were incubated with 10 nM Alexa488-Fn 9-10 and 0-100,000 nM of Fabs for 1.5 hr and subjecting to flow cytometry. Fab-binding was reported by changes in mean fluorescence intensity (MFI).
For determining EC 50 values for extension-stabilizing and open-stabilizing Fabs, we made the assumption that the increase in FP was directly proportional to the increase in concentration of Fab-bound open α 5 β 1 . This assumption is reasonable because the affinity of the EO conformation is so much higher than that of the BC and EC conformations for cRGD. Therefore, data were fit to a dose response curve:
where FP 0 is the FP without added Fab, FP sat and MFI sat are plateau values of FP and MFI, respectively, at high Fab concentration, and EC 50 is the Fab concentration at the inflection point where half-maximum change in FP or MFI was observed. The Fab's d for α 5 β 1 is approximated by EC 50 .
In the case of closure-stabilizing Fabs where α 5 β 1 was used at a high concentration in the assay, EC 50 significantly deviates from d due to depletion of Fab and FITC-cRGD. Therefore, we wrote equations S3-S10 as described below, and fit data to Eq. S11 below. In the assay, FITC-cRGD and its complex with α 5 β 1 free of Fab were the major sources of FP obs ; the α 5 β 1 ·Fab complex essentially does not bind FITC-cRGD due to its extremely low affinity, which was evident in Fig. 2 and Fig. S1 where at high concentrations of closure-stabilizing Fab, FP obs dropped to the value of free FITC-cRGD (0.09). Experimentally, α 5 β 1 was at 100 nM and cRGD was at 5 nM; in experiments to determine Fab d (Fig. S1 ) most of the FP signal was due to cRGD bound to the open α 5 β 1 conformation. Because the observed decrease in FP was due to Fabbinding to α 5 β 1 and stabilizing it in the closed conformation, we first wrote the equations for Fab-binding to α 5 β 1 and then considered the effect on α 5 β 1 binding to cRGD:
where ens(Basal):Fab d is Fab's d for α 5 β 1 , [α 5 β 1 ] tot and [Fab] tot are total concentrations of α 5 β 1 (100 nM) and closure-stabilizing Fab in the assay, respectively; [α 5 β 1 ] ′ is the concentration of Fab-free α 5 β 1 at equilibrium. In the following equations, we make the reasonable assumption that only Fab-free α 5 β 1 contributes to the FP signal:
where [L] tot is the total concentration of FITC-cRGD (5 nM); [α 5 β 1 ] is the concentration of free α 5 β 1 in the final mixture, and ens(Basal):L d is the affinity of α 5 β 1 for FITC-cRGD in the absence of Fabs, which was measured separately in a saturation binding assay (next section).
Solve Eq. S3-S8 for [α 5 β 1 ·L]:
where FP L and FP α 5 β 1 ·L are FP of free FITC-cRGD and α 5 , FP L and FP α 5 β 1 ·L .
Affinity of α 5 β 1 for ligand or for 12G10 Fab from saturation binding and Eqs. S12-S17 For soluble α 5 β 1 ectodomain or headpiece proteins, 0.1-10,000 nM α 5 β 1 were incubated with 5 nM FITC-cRGD or FITC-RGD ligand for 2 hr (24 hr in the presence of 12G10 Fab to reach equilibirum). Binding of FITC-cRGD or FITC-RGD was measured as FP. For intact α 5 β 1 , K562 cells (2×10 6 cells/mL) were incubated with 0.1-100 nM Alexa488-Fn 9-10 or Alexa488-12G10 Fab for 1.5 hr and subjected to flow cytometry. Binding of Alexa488-Fn 9-10 or Alexa488-12G10 was measured as mean fluorescence intensity (MFI). Using L to denote the fluorescent ligand or 12G10 Fab, at equilibrium:
where [α 5 β 1 ] tot is the total concentration of soluble α 5 β 1 in solution or total amount of α 5 β 1 on cell surface, [L] tot is the total concentration of the fluorescent ligand or 12G10 Fab, and app d is the apparent binding affinity of α 5 β 1 for ligand or 12G10 (defined in Eq. S47).
Solve Eq. S12-S14 for [α 5 β 1 ·L]:
Therefore, the measured FP (FP obs ) or MFI (MFI obs ) are
where FP L and FP α 5 β 1 ·L are FP of free and α 5 β 1 -bound FITC-cRGD or FITC-RGD, respectively, and MFI max is the MFI when all α 5 β 1 on cell surface are bound with Alexa488-Fn3 9-10 or Alexa488-12G10. Fitting the FP obs and [α 5 β 1 ] tot data to Eq. S16 yielded app d , FP L and FP α 5 β 1 ·L . Fitting the MFI obs and [L] tot data to Eq. S17 yielded app d and MFI max .
Affinity of intact α 5 β 1 for Fn3 9-10 and Eqs. S18-S26 K562 cells (2×10 6 cells/mL) were equilibrated with 1-10,000 nM Fn3 9-10 for 1.5 hr, followed by incubation with 0.4 nM Alexa488-12G10 Fab for 1.5 hr, and were subjected to flow cytometry. Both 12G10 and Fn3 9-10 stabilize the extended-open conformation. Alexa488-12G10 was used at a low concentration of 0.4 nM such that it did not show detectable binding to K562 cells in the absence of Fn3 9-10 and could be used to report stabilization by Fn3 9-10 of α 5 β 1 in the open conformation, which was only detectable at Fn3 9-10 concentrations above 100 nM. Therefore, we described reporting of the Fn3 9-10 -stabilized conformation of α 5 β 1 by changes in mean fluorescence intensity (MFI) of Alexa488-12G10 using the following equations in which Fn3 9-10 is denoted as L and Alexa488-12G10 is denoted as Fab:
where [α 5 β 1 ] tot is the total amount of α 5 β 1 on cell surface, [L] tot is the total concentration of Fn3 9-10 in the assay, [α 5 β 1 ·L] ′ is the concentration of α 5 β 1 ·Fn3 9-10 complex at equilibrium, and ens(Basal):L d is the affinity 5 for Fn3 9-10 .
where [Fab] tot is the total concentration of Alexa488-12G10 (0.4 nM); [α 5 β 1 ·L] is the final concentration of Alexa488-12G10-free α 5 β 1 ·Fn3 9-10 complex in the final mixture, and EO:Fab d is the affinity of α 5 β 1 ·Fn3 9-10 complex (in the extended-open conformation) for Alexa488-12G10, which was measured separately in a saturation binding assay (previous section).
Solve Eq. S18-S23 for [α 5 β 1 ·L·Fab]:
Therefore, the measured MFI (MFI obs ) is
where MFI max is the MFI when all α 5 β 1 on cell surface is bound to Alexa488-12G10. Fitting the MFI obs and [L] tot to Eq. S26 yielded ens(Basal):L d and MFI max .
Affinity of α 5 β 1 ectodomain for Fn3 9-10 from competitive binding and Eqs. S27-S28 α 5 β 1 ectodomain affinities for Fn3 9-10 was measured by using Fn3 9-10 to compete binding of FITC-cRGD peptide ligand. α 5 β 1 ectodomain (270 nM in the absence of Fabs, 20 nM in the presence of HUTS4 Fab, 90 nM in the presence of 8E3 Fab, or 70-10,000 nM in the presence of mAb13 Fab or mAb13 plus 9EG7 Fabs) was equilibrated with 0-10,000 nM Fn3 9-10 (competitor) for 2 hr. The mixture was incubated with 5 nM FITC-cRGD (ligand) for 2 hr, and FP was measured. Since only α 5 β 1 free of Fn3 9-10 could bind FITC-cRGD, the equations are identical to those for binding affinities for closure-stabilizing Fabs (Eq. S3-S11). Substituting Fab with C (for competitor) in Eq. S9 and S11:
where FP obs is the measured FP; FP L and FP α 5 β 1 ·L are FP of free FITC-cRGD and α 5 β 1 ·FITC-cRGD complex, respectively; [α 5 β 1 ] tot , [L] tot and [C] tot are total concentrations of α 5 β 1 , FITC-cRGD ligand (5 nM) and Fn3 9-10 competitor in the assay, respectively; [α 5 β 1 ] ′ is the concentration of Fn3 9-10 -free α 5 β 1 , either free of FITC-cRGD or with FITC-cRGD bound; app:C d and app:L d are apparent affinities of α 5 β 1 for Fn3 9-10 competitor and FITC-cRGD ligand, respectively.
For experiments in the absence of Fabs, or in the presence of HUTS4 or 8E3 Fab, fitting the FP obs and [C] tot data to Eq. S28 using the app:L d value measured separately in a saturation binding assay yielded 
If the Fab does not bind a state ( = BC, EC or EO), then a = 0 and [ ·Fab] = 0. For Fabs that bind two states and with equal affinities, i.e., a = a ( = EC and = EO for extension-stabilizing Fabs, = BC and = EC for closure-stabilizing Fabs), Fab-binding does not change the relative distribution of the two states:
The experimentally measured affinity of the basal ensemble for Fab, is a genuine equilibrium constant. Binding affinity is often expressed as dissociation constant ( d = 1/ a ) in the biological sciences to facilitate comparison to concentrations of the reactants. Following this convention, Eq. S33 can be rewritten as:
The total probability (population) of all Fab-bound species in the ensemble is For the α 5 β 1 headpiece, a similar analysis shows that at a sufficiently high concentration of Fab, the Fab-stabilized state dominates the ensemble.
In Eq. S39, [Fab] is the concentration of free Fab. In most experiments, Fabs are used at concentrations much higher than that of α 5 β 1 ; therefore, [Fab] can be approximated as the total Fab concentration minus the highest α 5 β 1 concentration used ([Fab] tot − [α 5 β 1 ] tot ) in calculating α 5 β 1 ·Fab :
True ligand-binding affinities ( ens d ) of α 5 β 1 conformational ensemble members and Eqs. S41-S72 We now consider using Fabs to stabilize conformational ensembles in specific states. A complication is that in the absence of 100% binding of the Fab, unbound α 5 β 1 can exist in other states. We derive the equations for determining the contributions of both Fab-bound α 5 β 1 ( α 5 β 1 ·Fab ) and unbound α 5 Eq. S47 can be rewritten using dissociation constants: Eq. S48-S49 can be rewritten using dissociation constants: Fig. S2 shows that α 5 β 1 ·Fab was > 99.8% for all closure-stabilizing Fab used here at concentrations shown in Table S1 , and that app(C Fab) d is indistinguishable from C d ; i.e., the difference between these quantities is smaller than the experimental error in C d . have no impact on the calculated probabilities (Fig. S2 ). Solve these equations for the probabilities, noting that BC + EC + EO = 1 (Eq. S37): 
Two-state ensembles
Calculation of free energy of each conformational state and Eqs. S78-S84 Using EO as the reference state (Δ EO = 0), the relative free energies of the BC and EC states, Δ BC and Δ EC , are related to the probabilities (populations) BC , EC and EO through the Boltzmann distribution (as also shown in Fig. 1C ):
where is known as the partition function. Solve Eq. S78-S81 for Δ BC and Δ EC , and substituting BC , EC and EO with Eq. S73-S75:
Likewise, for α 5 β 1 headpiece, using O as the reference state (Δ O = 0)
Calculation of free energies associated with conformational changes and Eqs. S85-S94 α 5 β 1 activation is associated with ectodomain extension and headpiece opening. These two types of conformational changes are not necessarily separate, independent steps; nor must they occur in a predefined order, allowing the conformational change among the three integrin states to be defined as from one state to another, or as interchange between one state and two other states. Indeed, we have previously described scenarios for different orders of steps 7 , and movies show how headpiece opening may either follow or precede extension (Supplemental Movies EV1-EV3). States such as bent-open may also be possible (Movie EV3); however, since these states have never been visualized by electron microscopy or small-angle X-ray scattering, their populations must be small, and thus the presence of their populations in the numerator or denominator of conf (defined below) has little effect on conf values. Extension from BC to EC defines E conf and its associated free energy Δ E conf : Binding of closure-stabilizing Fab SG/19 to α 5 β 1 (100 nM) influenced binding of FITC-cRGD (5 nM) to α 5 β 1 as monitored by FP. d values were obtained from fitting the FP data to Eq. S11. Errors are fitting errors from triplicates. Clasped complex N-glycan α 5 
